Telomir Pharmaceuticals Inc
Company Profile
Business description
Telomir Pharmaceuticals Inc is a preclinical-stage biotechnology company focused on the development of small-molecule therapeutics designed to address upstream biological drivers of aging and age-related diseases rather than treating symptoms alone. The company's research targets fundamental cellular processes associated with disease progression and functional decline, including metal-ion dysregulation, oxidative stress, epigenetic regulation, mitochondrial dysfunction, and telomere integrity. Telomir's investigational compound, Telomir-1 (Zn-Telomir), is a novel orally administered small molecule engineered to modulate intracellular metal balance particularly iron, copper, calcium, and zinc.
Contact
100 SE, 2nd Street
Suite 2000, No.1009
MiamiFL33131
USAT: +1 786 396-6723
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
Stocks News & Analysis
stocks
Chart of the Week: BHP’s growth story faces a reality check
stocks
3 best ASX growth stocks to buy for the long term
stocks
The ASX data center stock flying under the radar
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,036.90 | 13.00 | -0.14% |
| CAC 40 | 8,311.62 | 70.81 | -0.84% |
| DAX 40 | 24,814.99 | 184.54 | -0.74% |
| Dow JONES (US) | 52,658.64 | 150.37 | 0.29% |
| FTSE 100 | 10,476.24 | 39.68 | -0.38% |
| HKSE | 25,008.60 | 327.50 | 1.33% |
| NASDAQ | 26,269.23 | 162.22 | 0.62% |
| Nikkei 225 | 66,835.54 | 1,915.97 | -2.79% |
| NZX 50 Index | 13,614.78 | 20.29 | -0.15% |
| S&P 500 | 7,572.40 | 28.81 | 0.38% |
| S&P/ASX 200 | 8,840.70 | 15.50 | -0.18% |
| SSE Composite Index | 3,882.41 | 73.17 | -1.85% |